Metsera, Inc. (NASDAQ:MTSR – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Metsera in a research note issued to investors on Tuesday, February 25th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($3.38) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.
MTSR has been the subject of a number of other reports. Bank of America started coverage on shares of Metsera in a report on Tuesday. They set a “buy” rating and a $38.00 target price for the company. Guggenheim began coverage on Metsera in a research note on Tuesday. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, Evercore ISI started coverage on shares of Metsera in a report on Tuesday. They issued an “outperform” rating for the company.
Metsera Stock Down 0.4 %
Metsera stock opened at $27.21 on Thursday. Metsera has a 52-week low of $25.06 and a 52-week high of $32.81.
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
- Five stocks we like better than Metsera
- Differences Between Momentum Investing and Long Term Investing
- These Consumer Staples Shine Amid Market Turmoil
- Manufacturing Stocks Investing
- Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Axon: Long-Term Outlook Is Strong Despite Federal Budget Worries
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
